Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara Fonteneau

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Elife|April 17, 2024
Ketamine induces multiple individually distinct whole-brain functional connectivity signaturesFlora Moujaes, Jie Lisa Ji, Masih Rahmati, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical TrialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Journal of Psychiatric Research|January 10, 2026
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Elife|April 17, 2024
Ketamine induces multiple individually distinct whole-brain functional connectivity signaturesFlora Moujaes, Jie Lisa Ji, Masih Rahmati, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical TrialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Journal of Psychiatric Research|January 10, 2026
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 3